Quick Answer
Anika Therapeutics, Inc. reported Operating Income of -$11.05 million for fiscal year 2025.
Anika Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$11.05M | -116.6% |
| 2024 | -$5.10M | -704.4% |
| 2023 | $844.0K | -77.0% |
| 2022 | $3.67M | +40.3% |
| 2021 | $2.62M | +109.2% |
| 2020 | -$28.32M | -182.7% |
| 2019 | $34.25M | +57.5% |
| 2018 | $21.75M | -52.4% |
| 2017 | $45.73M | -9.6% |
| 2016 | $50.61M | +5.1% |
| 2015 | $48.13M | -21.7% |
| 2014 | $61.45M | +88.4% |
| 2013 | $32.61M | +65.4% |
| 2012 | $19.72M | +41.2% |
| 2011 | $13.97M | +85.3% |
| 2010 | $7.54M | +34.9% |
| 2009 | $5.59M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.23M | -3891.4% | +22.7% |
| June 30, 2025 | -$4.18M | -130.9% | +2.4% |
| March 31, 2025 | -$4.28M | -71.0% | -5188.9% |
| September 30, 2024 | -$81.0K | +98.9% | +95.5% |
| June 30, 2024 | -$1.81M | +50.2% | +27.7% |
| March 31, 2024 | -$2.50M | +80.0% | +67.4% |
| September 30, 2023 | -$7.67M | -32.4% | -111.3% |
| June 30, 2023 | -$3.63M | -7.4% | +71.1% |
- Anika Therapeutics, Inc. showed a decrease of -116.6% in Operating Income compared to the prior fiscal year.
- Over the 2009–2025 period, Anika Therapeutics, Inc.’s operating income has declined by 297.8% (from $5.59 million to -$11.05 million).
- The most recent figure is from Anika Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: